Unlock instant, AI-driven research and patent intelligence for your innovation.

Nucleic acids for inhibiting expression of pros1 in a cell

a technology of nucleic acids and pros1, which is applied in the field of nucleic acid products, can solve the problems of complex process for detecting potent nucleic acid silencing triggers with minimal off-target effects, severe limitations, and disability at a young ag

Pending Publication Date: 2022-05-05
SILENCE THERAPEUTIC AG +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a new invention that allows for the specific delivery of siRNA to target genes. The nucleic acids in the invention have a high level of specificity for their target, meaning they do not affect other genes or only minimally. This is achieved through the use of a ligand that is specifically recognised and internalised by a particular cell type. This provides a safer profile compared to current treatments. In some cases, the nucleic acid can also be designed to specifically target a certain gene. Overall, this technology has the potential to be highly effective and targeted in treating gene-related diseases.

Problems solved by technology

According to Watts and Corey in the Journal of Pathology (2012; Vol 226, p 365-379), there are algorithms that can be used to design nucleic acid silencing triggers, but all of these have severe limitations.
Therefore, the discovery of a potent nucleic acid silencing trigger with minimal off-target effects is a complex process.
This can result in disability at a young age if left untreated.
Likewise, without Protein S, APC is inefficient at inhibiting FVa and FVIIIa.
As a consequence, loss of function mutations of Protein S cause uncontrolled coagulation in mice and in humans.
However, replacement therapy can be compromised by the development of alloantibodies to FVIII and FIX.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleic acids for inhibiting expression of pros1 in a cell
  • Nucleic acids for inhibiting expression of pros1 in a cell
  • Nucleic acids for inhibiting expression of pros1 in a cell

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Building Blocks

[0567]The synthesis route for DMT-Serinol (GalNAc)-CEP and CPG as described below is outlined in FIG. 1. Starting material DMT-Serinol(H) (1) was made according to literature published methods (Hoevelmann et al. Chem. Sci., 2016, 7, 128-135) from commercially available L-Serine. GalNAc(Ac3)—C4H8—COOH (2) was prepared according to literature published methods (Nair et al. J. Am. Chem. Soc., 2014, 136 (49), pp 16958-1696), starting from commercially available per-acetylated galactose amine. Phosphitylation reagent 2-Cyanoethyl-N,N-diisopropylchlorophosphor-amidite (4) is commercially available. Synthesis of (vp)-mU-phos was performed as described in Prakash, Nucleic Acids Res. 2015, 43(6), 2993-3011 and Haraszti, Nucleic Acids Res. 2017, 45(13), 7581-7592. Synthesis of the phosphoramidite derivatives of ST43 (ST43-phos) as well as ST23 (ST23-phos) and similar can be performed as described in WO2017 / 174657.

[0568]DMT-Serinol(GalNAc) (3)

[0569]HBTU (9.16 g, 24.14 mmol) w...

example 2

eotide Synthesis

[0576]Example compounds were synthesised according to methods described below and known to the person skilled in the art. Assembly of the oligonucleotide chain and linker building blocks was performed by solid phase synthesis applying phosphoramidite methodology.

[0577]Downstream cleavage, deprotection and purification followed standard procedures that are known in the art.

[0578]Oligonucleotide syntheses was performed on an AKTA oligopilot 10 using commercially available 2′O-Methyl RNA and 2′Fluoro-2′Deoxy RNA base loaded CPG solid support and phosphoramidites (all standard protection, ChemGenes, LinkTech) were used. Synthesis of DMT-(S)-Serinol(GalNAc)-succinyl Icaa CPG (7) and DMT-(S)-Serinol(GalNAc)-CEP (5) are described in example 1.

[0579]Ancillary reagents were purchased from EMP Biotech. Synthesis was performed using a 0.1 M solution of the phosphoramidite in dry acetonitrile (2O) and benzylthiotetrazole (BTT) was used as activator (0.3M in acetonitrile). Coupli...

example 3

rand Formation

[0585]Individual single strands were dissolved in a concentration of 60 OD / ml in H2O. Both individual oligonucleotide solutions were added together in a reaction vessel. For easier reaction monitoring a titration was performed. The first strand was added in 25% excess over the second strand as determined by UV-absorption at 260 nm. The reaction mixture was heated to 80° C. for 5 min and then slowly cooled to RT. Double-strand formation was monitored by ion pairing reverse phase HPLC. From the UV-area of the residual single strand the needed amount of the second strand was calculated and added to the reaction mixture. The reaction was heated to 80° C. again and slowly cooled to RT. This procedure was repeated until less than 10% of residual single strand was detected.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Interferenceaaaaaaaaaa
Lengthaaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to View More

Abstract

The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a Continuation of International Patent Application No. PCT / EP2021 / 080302, filed on Nov. 2, 2021, which claims the benefit of European Patent Application No. 20205642.0, filed on Nov. 4, 2020, and European Patent Application No. 21163570.1, filed on Mar. 18, 2021. The contents of the foregoing patent applications are incorporated by reference herein in their entirety.FIELD OF THE INVENTION[0002]The invention relates to nucleic acid products that interfere with or inhibit PROS1 (Protein S) gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.BACKGROUND[0003]Double-stranded RNAs (dsRNA) able to bind through complementary base pairing to expressed mRNAs have been shown to block gene expression (Fire et al., 1998, Nature. 1998 Feb. 19; 391(6669):806-11 and Elbashir et al., 2001, Nature. 2001 May 24; 411(6836):494-8) by a mechanism that has been termed “RNA interference (RNA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113A61P7/04
CPCC12N15/113A61P7/04C12N2310/322C12N2310/14C12N2310/351C12N2320/30C12N2310/315C12N15/1137C12N2310/313C12N2310/317C12N2310/312C12N2310/321C12N2310/3515C12N2310/3521C12N2310/3533
Inventor SCHAEPER, UTEDAMES, SIBYLLEMORRISON, ELIOTPRINCE ELADNANI, RAJAANGELILLO-SCHERRER, ANNE
Owner SILENCE THERAPEUTIC AG